BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models

Jeremy M. Kinder(Sana Biotechnology (United States)), Aaron E. Foster(Medpace (United States)), Chanel Athena-Estrada(Sana Biotechnology (United States)), Danyal Malik(Sana Biotechnology (United States)), Terry J. Fry(University of Colorado Anschutz Medical Campus), Neal Van Hoeven(Sana Biotechnology (United States)), Jesus Moreno(Sana Biotechnology (United States)), Garrett Zipp(Sana Biotechnology (United States)), Sonja Schrepfer(Cedars-Sinai Medical Center), Chi Young(Sana Biotechnology (United States)), Ouwen Liang(Sana Biotechnology (United States)), Aaron Lampano(Fred Hutch Cancer Center), Brian Granger(Sana Biotechnology (United States)), Xiaomeng Hu(Huzhou University), Adam Johnson(Sana Biotechnology (United States)), Vandana Chaturvedi(Sana Biotechnology (United States)), Meghan Lamba(Sana Biotechnology (United States))
Blood
November 15, 2022
Cited by 1


Related Papers